Format

Send to

Choose Destination
Gac Med Mex. 2004 Sep-Oct;140(5):547-52.

[All-trans retinoic acid syndrome. Case report and a review of the literature].

[Article in Spanish]

Author information

1
Servicio de terapia intensiva, HCSAE PEMEX. seconcapcma@mail.medinet.net.mx

Abstract

We described a patient with acute promyelocytic leukemia (APL) who developed all-trans retinoic acid syndrome (ATRAS) and reviewed the literature. ATRAS presents in patients with APL treated with all-trans retinoic acid (ATRA). It has an incidence from 5%-27% with mortality of 29%. It is secondary to ATRA effect on promyelocyte differentiation, which causes systemic inflammatory response syndrome, endothelium damage with increase in capillary permeability, microcirculation obstruction, and tissue infiltration. ATRAS clinical manifestations are fever, hypotension, respiratory, renal and hepatic insufficiency, lung infiltrates, pleural and pericardic effusion, and generalized edema. Treatment is based on ATRA suspension, support measures, and steroids.

PMID:
15559237
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center